GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Vicadrostat

Company
Boehringer Ingelheim
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Vicadrostat and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06424288

    A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

    Not yet reported Boehringer Ingelheim 6000 participants Est. completion 2028-05-22 652 sites Stand-alone
    Heart failure
    View official trial listing →
  • Recruiting NCT NCT06531824

    EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

    Not yet reported Boehringer Ingelheim 11000 participants Est. completion 2028-08-30 520 sites Stand-alone
    Other conditions: Kidney Disease, Chronic
    View official trial listing →
  • Recruiting NCT NCT06935370

    A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

    Not yet reported Boehringer Ingelheim 4200 participants Est. completion 2029-02-22 588 sites Stand-alone
    Heart failure
    View official trial listing →
  • Recruiting NCT NCT07064473

    EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

    Not yet reported Boehringer Ingelheim 11800 participants Est. completion 2029-12-21 1143 sites Stand-alone
    Type 2 diabetesCardiovascular disease Other conditions: Hypertension
    View official trial listing →
  • Recruiting NCT NCT07304817

    Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

    Not yet reported University Medical Center Groningen 100 participants Est. completion 2028-02 2 sites Stand-alone
    Chronic kidney diseaseCardiovascular diseaseHeart failure
    View official trial listing →
  • Completed NCT NCT02891148

    Single Rising Dose Study of BI 690517 in Healthy Volunteers

    Not yet reported Boehringer Ingelheim 50 participants Est. completion 2016-12-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03100916

    This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

    Not yet reported Boehringer Ingelheim 72 participants Est. completion 2017-11-24 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03165240

    This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

    Not yet reported Boehringer Ingelheim 62 participants Est. completion 2020-05-07 40 sites Stand-alone
    Other conditions: Diabetic Nephropathies
    View official trial listing →
  • Completed NCT NCT03206632

    This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated

    Not yet reported Boehringer Ingelheim 56 participants Est. completion 2017-10-13 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03608072

    A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated

    Not yet reported Boehringer Ingelheim 36 participants Est. completion 2019-01-31 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05182840

    A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

    Not yet reported Boehringer Ingelheim 714 participants Est. completion 2023-07-10 203 sites Stand-alone
    Other conditions: Kidney Disease, Chronic
    View official trial listing →
  • Completed NCT NCT05515588

    A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

    Not yet reported Boehringer Ingelheim 14 participants Est. completion 2022-11-17 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05731908

    A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

    Not yet reported Boehringer Ingelheim 28 participants Est. completion 2023-04-13 2 sites Stand-alone
    Other conditions: Liver Diseases, Healthy
    View official trial listing →
  • Completed NCT NCT06647810

    A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood

    Not yet reported Boehringer Ingelheim 15 participants Est. completion 2025-01-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06926660

    A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

    Not yet reported Boehringer Ingelheim 492 participants Est. completion 2026-08-14 157 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT07035457

    A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

    Not yet reported Boehringer Ingelheim 15 participants Est. completion 2025-08-15 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT07133399

    A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood

    Not yet reported Boehringer Ingelheim 32 participants Est. completion 2025-10-22 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT07513207

    A Study in Healthy People to Test How Vicadrostat Affects the Heart

    Not yet reported Boehringer Ingelheim 45 participants Est. completion 2026-08-21 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Vicadrostat, BI 690517

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.